Levosimendan Tillomed (Levosimendan)

Levosimendan works by binding to troponin C in cardiac muscle, which increases the sensitivity of the contractile proteins to calcium without raising intracellular calcium concentrations. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation and reducing cardiac workload.

The dosing regimen for Levosimendan Tillomed is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. It is administered intravenously under continuous monitoring, and the exact infusion rate and duration are individualized for each patient.

Safety data for levosimendan in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To order Levosimendan Tillomed, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Compared with traditional inotropes such as dobutamine or milrinone, levosimendan increases contractility without a large rise in intracellular calcium, which may reduce the risk of arrhythmias. It also provides vasodilatory effects, offering combined inotropic and afterload‑reducing benefits that can be advantageous in certain heart‑failure patients.

Levosimendan Tillomed should be stored at 2‑8 °C, protected from light, and must not be frozen. The product should be kept in its original packaging to maintain stability, and any reconstituted solution should be used within the time frame specified by the manufacturer.

Levosimendan is given as an intravenous infusion, usually preceded by a loading dose followed by a continuous maintenance infusion. Administration is performed in a setting where cardiac monitoring and blood pressure measurement are available, allowing rapid adjustment of the infusion rate as needed.

The most serious risks include severe hypotension, life‑threatening arrhythmias, myocardial ischemia, and rare allergic reactions such as anaphylaxis. Patients should be closely monitored for these events, especially during the initial infusion period.

Levosimendan is contraindicated in patients with severe hypotension, mechanical obstruction of the outflow tract, known hypersensitivity to the drug, and in those receiving certain strong vasodilators that could precipitate dangerous blood‑pressure drops. Clinical judgment is required for patients with significant renal or hepatic impairment.